article thumbnail

Stroke Survivors With Afib Could Start DOACs Earlier

Med Page Today

(MedPage Today) -- It was safe to start direct oral anticoagulant (DOAC) therapy without delay after acute ischemic stroke in people with atrial fibrillation (Afib), according to the OPTIMAS randomized trial. Stroke survivors randomized to early.

AFIB 116
article thumbnail

New Data Available for Minimally Invasive Treatment of AFib

DAIC

18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. A statistically significant lower number of fatal or disabling strokes with Amulet (22 vs. 39). vs. 90.9%). vs. 83.3%).

AFIB 52
article thumbnail

Afib Detected After Stroke: Link to Recurrent Events Questioned

Med Page Today

(MedPage Today) -- Cryptogenic stroke survivors who went on to get an insertable cardiac monitor (ICM) had a similar risk of recurrent stroke whether or not any atrial fibrillation (Afib, AF) ever turned up on monitoring, an observational study.

AFIB 105
article thumbnail

Regular dental flossing may lower risk of stroke from blood clots, irregular heartbeats

Science Daily - Heart Disease

People who regularly floss their teeth (one or more times per week) may lower their risk of stroke caused by a blood clot traveling from the heart and a stroke associated with an irregular heartbeat such as atrial fibrillation (AFib).

article thumbnail

Abelacimab Stops Bleeding, But Stroke Impact Uncertain

CardiacWire

Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up.

Stroke 59
article thumbnail

Novartis Reclaims Anthos, Reenters Factor XI Race

CardiacWire

Bayer terminated its OCEANIC-AF trial for its Factor XI inhibitor, asundexian, due to 3x greater stroke (1.3% vs. 0.4%) and 4x higher ischemic stroke rates (csHR = 4.06). Results from BMS AXIOMATIC-SSP study found that its Factor XI inhibitor, milvexian, failed to meaningfully reduce ischemic stroke.

AFIB 102
article thumbnail

State-of-the-Art Review Examines LAAO as Therapy For Stroke Prevention in Patients With AFib

American College of Cardiology

he utility of left atrial appendage occlusion (LAAO) as a therapy for stroke prevention in patients with nonvalvular atrial fibrillation (AFib) is the focus of a State-of-the-Art Review published Jan. 8 in JACC: Clinical Electrophysiology.

AFIB 75